Tumour regression predicts better response to interferon therapy in melanoma patients: a retrospective single centre study.
Journal
Melanoma research
ISSN: 1473-5636
Titre abrégé: Melanoma Res
Pays: England
ID NLM: 9109623
Informations de publication
Date de publication:
13 Nov 2023
13 Nov 2023
Historique:
medline:
14
11
2023
pubmed:
14
11
2023
entrez:
14
11
2023
Statut:
aheadofprint
Résumé
We hypothesise that regression may have an impact on the effectiveness of adjuvant IFN therapy, based on its role in the host immune response. Our purpose is to investigate regression and ulceration as prognostic factors in case of interferon-alpha (IFN)-treated melanoma patients. We followed 357 IFN-treated melanoma patients retrospectively, investigating progression-free survival (PFS) and overall survival (OS) depending on the presence of ulceration and regression. A Kaplan-Meier analysis was performed, and we used a Cox regression analysis to relate risk factors. The survival function of the Cox regression was used to measure the effect of regression and ulceration on PFS and OS depending on the Breslow thickness (T1-T4) of the primary tumour. Regression was significantly positively related to PFS (P = 0.0018, HR = 0.352) and OS (P = 0.0112, HR = 0.380), while ulceration showed a negative effect (PFS: P = 0.0001, HR = 2.629; OS: P = 0.0001, HR = 2.388). They influence survival independently. The most favourable outcome was measured in the regressed/non-ulcerated group, whereas the worse was in the non-regressed/ulcerated one. Of risk factors, Breslow thickness is the most significant predictor. The efficacy of regression is regardless of Breslow thickness, though the more favourable the impact of regression was in the thicker primary lesions. Our results indicate that regression is associated with a more favourable outcome for IFN-treated melanoma patients, whereas ulceration shows an inverse relation. Further studies are needed to analyse the survival benefit of regression in relation to innovative immune checkpoint inhibitors.
Identifiants
pubmed: 37962233
doi: 10.1097/CMR.0000000000000935
pii: 00008390-990000000-00113
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
American Cancer Society Cancer Facts & Figures 2016. American Cancer Society: Atlanta, GA, 2016.
Balch CM, Wilkerson JA, Murad TM, Soong SJ, Ingalls AL, Maddox WA. The prognostic significance of ulceration of cutaneous melanoma. Cancer 1980; 45:3012–3017.
Måsbäck A, Olsson H, Westerdahl J, Ingvar C, Jonsson N. Prognostic factors in invasive cutaneous malignant melanoma: a population-based study and review. Melanoma Res 2001; 11:435–445.
Grande Sarpa H, Reinke K, Shaikh L, Leong SP, Miller JR 3rd, Sagebiel RW, et al. Prognostic significance of extent of ulceration in primary cutaneous melanoma. Am J Surg Pathol 2006; 30:1396–1400.
Mascaro JM, Castro J, Castel T, Lecha M, Gratacos R, Mascaro JM Jr. Why do melanomas ulcerate? J Cutan Pathol 1984; 11:269–273.
Kashani-Sabet M, Shaikh L, Miller JR 3rd, Nosrati M, Ferreira CM, Debs RJ, et al. NF-kappa B in the vascular progression of melanoma. J Clin Oncol 2004; 22:617–623.
Kashani-Sabet M, Sagebiel RW, Ferreira CM, Nosrati M, Miller JR 3rd. Tumor vascularity in the prognostic assessment of primary cutaneous melanoma. J Clin Oncol. 2002;20(7):1826–31.
McMasters KM, Edwards MJ, Ross MI, Reintgen DS, Martin RC 2nd, Urist MM, et al. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma. Ann Surg 2010; 252:460–5; discussion 465-6.
Karina A. Regression in cutaneous melanoma: histological assessment, immune mechanisms and clinical implications. Pathology (Phila) 2023; 55:227–235.
Shon W, Frishberg D, Gershenwald J. ‘Protocol for the examination of biopsy specimens from patients with melanoma of the skin, version 4.2. 0.0. College of American Pathologists (CAP); 2019.
Aung PP, Nagarajan P, Prieto VG. Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance. Lab Invest 2017; 97:657–668.
Ronan SG, Eng AM, Briele HA, Shioura NN, Das Gupta TK. Thin malignant melanomas with regression and metastases. Arch Dermatol 1987; 123:1326–1330.
Blessing K, McLaren KM, McLean A, Davidson P. Thin malignant melanomas (less than 15 mm) with metastasis: a histological study and survival analysis. Histopathology 1990; 17:389–395.
Blessing K, McLaren KM. Histological regression in primary cutaneous melanoma: recognition, prevalence and significance. Histopathology 1992; 20:315–322.
Guitart J, Lowe L, Piepkorn M, Prieto VG, Rabkin MS, Ronan SG, et al. Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol 2002; 138:603–608.
Morton DL, Cochran AJ, Thompson JF, Elashoff R, Essner R, Glass EC, et al.; Multicenter Selective Lymphadenectomy Trial Group. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 2005; 242:302–11; discussion 311-3.
Barnhill RL, Fine JA, Roush GC, Berwick M. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer 1996; 78:427–432.
Testori A, De Salvo GL, Montesco MC, Trifirò G, Mocellin S, Landi G, et al.; Italian Melanoma Intergroup. Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM-IMI). Ann Surg Oncol 2009; 16:2018–2027.
Ribero S, Osella-Abate S, Sanlorenzo M, Savoia P, Astrua C, Cavaliere G, et al. Favourable prognostic role of regression of primary melanoma in AJCC stage I-II patients. Br J Dermatol 2013; 169:1240–1245.
Zugna D, Senetta R, Osella-Abate S, Fierro MT, Pisacane A, Zaccagna A, et al. Favourable prognostic role of histological regression in stage III positive sentinel lymph node melanoma patients. Br J Cancer 2018; 118:398–404.
Di Trolio R, Simeone E, Di Lorenzo G, Buonerba C, Ascierto PA. The use of interferon in melanoma patients: a systematic review. Cytokine Growth Factor Rev 2015; 26:203–212.
Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med 2011; 208:2005–2016.
Kirkwood JM, Richards T, Zarour HM, Sosman J, Ernstoff M, Whiteside TL, et al. Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer 2002; 95:1101–1112.
Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354:709–718.
Gogas H, Abali H, Ascierto PA, Demidov L, Pehamberger H, Robert C, et al. Who benefits most from adjuvant interferon treatment for melanoma? Am J Ther 2015; 22:54–60.
Ives NJ, Suciu S, Eggermont AMM, Kirkwood J, Lorigan P, Markovic SN, et al.; International Melanoma Meta-Analysis Collaborative Group (IMMCG). Adjuvant interferon-α for the treatment of high-risk melanoma: an individual patient data meta-analysis. Eur J Cancer 2017; 82:171–183.
McMasters KM, Wong SL, Edwards MJ, Ross MI, Chao C, Noyes RD, et al. Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. Surgery 2001; 130:151–156.
Blessing K, McLaren KM. Histological regression in primary cutaneous melanoma: recognition, prevalence and significance. Histopathology 1992; 20:315–322.
Requena C, Botella-Estrada R, Traves V, Nagore E, Almenar S, Guillén C. Regresión en el melanoma: problemas en su definición e implicación pronóstica [Problems in defining melanoma regression and prognostic implication]. Actas Dermosifiliogr 2009; 100:759–766.
Ribero S, Moscarella E, Ferrara G, Piana S, Argenziano G, Longo C. Regression in cutaneous melanoma: a comprehensive review from diagnosis to prognosis. J Eur Acad Dermatol Venereol 2016; 30:2030–2037.
Ma MW, Medicherla RC, Qian M, Vega-Saenz de Miera E, Friedman EB, Berman RS, et al. Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node. Mod Pathol 2012; 25:1000–1010.
Weber JS, Hamid O, Chasalow SD, Wu DY, Parker SM, Galbraith S, et al. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. J Immunother 2012; 35:89–97.
Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517–2526.
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372:320–330.
Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134–144.
Fukuda K. Networks of CD8 + T cell response activation in melanoma and vitiligo. Front Immunol 2022; 13. doi: 10.3389/fimmu.2022.866703
doi: 10.3389/fimmu.2022.866703
van Geel NA, Mollet IG, De Schepper S, Tjin EP, Vermaelen K, Clark RA, et al. First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi. Pigment Cell Melanoma Res 2010; 23:375–384.
Failla CM, Carbone ML, Fortes C, Pagnanelli G, D’Atri S. Melanoma and vitiligo: in good company. Int J Mol Sci 2019; 20:5731.
Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with Pembrolizumab. JAMA Dermatol. 2016; 152:45–51.
Kocsis A, Mezőlaki N, Porkoláb D, Mohos G, Kis E, Varga J, et al. Az őrszemnyirokcsomó-áttét kimutatása 4 mm-nél vastagabb melanomában esélyt ad ígéretes adjuváns kezelésre [Detection of sentinel lymph node metastasis in thick melanoma provides promising adjuvant treatment]. Orv Hetil 2020; 161:1675–1680.
Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, et al.; MSLT Group. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 2014; 370:599–609.
Ribero S, Osella-Abate S, Sanlorenzo M, Balagna E, Senetta R, Fierro MT, et al. Sentinel lymph node biopsy in thick-melanoma patients (N=350): what is its prognostic role? Ann Surg Oncol 2015; 22:1967–1973.
Oláh J, Gyulai R, Korom I, Varga E, Dobozy A. Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas. Br J Dermatol 2003; 149:662–663.
Kruper LL, Spitz FR, Czerniecki BJ, Fraker DL, Blackwood-Chirchir A, Ming ME, et al. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma. Cancer 2006; 107:2436–2445.
Cecchi R, Pavesi M, Buralli L, Innocenti S, De Gaudio C. Tumour regression does not increase the risk of sentinel node involvement in thin melanomas. Chir Ital 2008; 60:257–260.
Gutzmer R, Satzger I, Thoms KM, Völker B, Mitteldorf C, Kapp A, et al. Sentinel lymph node status is the most important prognostic factor for thick (> or = 4 mm) melanomas. J Dtsch Dermatol Ges 2008; 6:198–203.
Letca AF, Ungureanu L, Şenilă SC, Grigore LE, Pop S, Fechete O, et al. Regression and sentinel lymph node status in melanoma progression. Med Sci Monit 2018; 24:1359–1365.
Liszkay G, Orosz Z, Péley G, Csuka O, Plótár V, Sinkovics I, et al. Relationship between sentinel lymph node status and regression of primary malignant melanoma. Melanoma Res 2005; 15:509–513.
Morris KT, Busam KJ, Bero S, Patel A, Brady MS. Primary cutaneous melanoma with regression does not require a lower threshold for sentinel lymph node biopsy. Ann Surg Oncol 2008; 15:316–322.